Relay Therapeutics director proposes $1.29M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. director Sekar Kathiresan filed a notice of a proposed sale of 66,055 common shares, with an aggregate market value of $1,293,555.07 and an approximate sale date of July 20, 2026. The notice says the shares were acquired from the issuer through a stock option exercise on July 20, 2026, with cash payment.
Key Figures
Key Terms
Stock Option Exercise financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.